Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
729 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04990479 | Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma | terminated | Phase 1 | 7 | Nouscom SRLINDUSTRY | 3 | Mar 20, 2025 | clinicaltrials |
| NCT02098343 | p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 | completed | Phase 1 / Phase 2 | 247 | Aprea TherapeuticsINDUSTRY | 8 | Mar 17, 2025 | clinicaltrials |
| NCT01836705 | Effect of SAR302503 on ECG Activity in Patients With Solid Tumors | completed | Phase 1 | 60 | Bristol-Myers SquibbINDUSTRY | 2 | Mar 5, 2025 | clinicaltrials |
| NCT05087992 | A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers | completed | Phase 1 | 13 | Boehringer IngelheimINDUSTRY | 5 | Feb 19, 2025 | clinicaltrials |
| NCT04041050 | A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | active not recruiting | Phase 1 | 85 | AbbVieINDUSTRY | 14 | Feb 14, 2025 | clinicaltrials |
| NCT03371381 | An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung | terminated | Phase 1 / Phase 2 | 12 | Janssen Research & Development, LLCINDUSTRY | 3 | Feb 4, 2025 | clinicaltrials |
| NCT03610581 | Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix | terminated | Phase 1 / Phase 2 | 9 | Janssen Vaccines & Prevention B.V.INDUSTRY | 2 | Feb 4, 2025 | clinicaltrials |
| NCT06411301 | A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors(AcTRESS) | withdrawn | Phase 1 | 0 | Jules Bordet InstituteOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT04046445 | Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer(KISIMA-01) | active not recruiting | Phase 1 | 96 | Amal TherapeuticsINDUSTRY | 4 | Jan 29, 2025 | clinicaltrials |
| NCT03523572 | Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer | completed | Phase 1 | 86 | Daiichi SankyoINDUSTRY | 7 | Jan 27, 2025 | clinicaltrials |
| NCT03127007 | Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer(R-IMMUNE) | completed | Phase 1 / Phase 2 | 45 | Grand Hôpital de CharleroiOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06097975 | A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma(NEO-GLITIPNI) | recruiting | Phase 1 | 18 | Universitair Ziekenhuis BrusselOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT03936959 | A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer | terminated | Phase 1 | 10 | Eli Lilly and CompanyINDUSTRY | 5 | Jan 15, 2025 | clinicaltrials |
| NCT04727554 | Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors | completed | Phase 1 | 11 | AmgenINDUSTRY | 10 | Jan 6, 2025 | clinicaltrials |
| NCT03616886 | Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC(SYNERGY) | active not recruiting | Phase 1 / Phase 2 | 129 | Jules Bordet InstituteOTHER | 2 | Dec 19, 2024 | clinicaltrials |
| NCT03922204 | A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies | completed | Phase 1 | 72 | Merus B.V.INDUSTRY | 4 | Dec 11, 2024 | clinicaltrials |
| NCT01291420 | Dendritic Cell Vaccination for Patients with Solid Tumors | completed | Phase 1 / Phase 2 | 48 | University Hospital, AntwerpOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT03671018 | A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 422 | Hoffmann-La RocheINDUSTRY | 5 | Nov 29, 2024 | clinicaltrials |
| NCT02054351 | Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)(OVAR) | completed | Phase 1 | 42 | Ganymed Pharmaceuticals GmbHINDUSTRY | 2 | Nov 21, 2024 | clinicaltrials |
| NCT03356860 | Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.(B-IMMUNE) | completed | Phase 1 / Phase 2 | 57 | Grand Hôpital de CharleroiOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT03845166 | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors(STELLAR-001) | active not recruiting | Phase 1 | 325 | ExelixisINDUSTRY | 10 | Nov 19, 2024 | clinicaltrials |
| NCT01084252 | Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies | completed | Phase 1 / Phase 2 | 351 | SanofiINDUSTRY | 17 | Nov 1, 2024 | clinicaltrials |
| NCT03215511 | A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer | completed | Phase 1 | 81 | BayerINDUSTRY | 10 | Oct 30, 2024 | clinicaltrials |
| NCT05289492 | Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 | 16 | iTeos TherapeuticsINDUSTRY | 4 | Oct 26, 2024 | clinicaltrials |
| NCT04358458 | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas | terminated | Phase 1 / Phase 2 | 46 | GenmabINDUSTRY | 5 | Oct 24, 2024 | clinicaltrials |
| NCT03126591 | A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma | completed | Phase 1 | 41 | Eli Lilly and CompanyINDUSTRY | 4 | Oct 23, 2024 | clinicaltrials |
| NCT04134936 | Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL | completed | Phase 1 | 66 | MorphoSys AGINDUSTRY | 9 | Oct 16, 2024 | clinicaltrials |
| NCT01370551 | Clinical Study of Vaginal Lactobacilli and Estriol (Gynoflor®) for Atrophic Vaginitis in Breast Cancer Patients(Gynoflor) | completed | Phase 1 | 16 | Medinova AGINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT02516813 | Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy | completed | Phase 1 | 52 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 8 | Oct 15, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT05315713 | An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 8 | Hoffmann-La RocheINDUSTRY | 6 | Oct 4, 2024 | clinicaltrials |
| NCT03875079 | A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma | completed | Phase 1 | 83 | Hoffmann-La RocheINDUSTRY | 7 | Oct 3, 2024 | clinicaltrials |
| NCT02791334 | A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors(PACT) | completed | Phase 1 | 164 | Eli Lilly and CompanyINDUSTRY | 7 | Sep 27, 2024 | clinicaltrials |
| NCT05298592 | A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors | completed | Phase 1 | 77 | Bristol-Myers SquibbINDUSTRY | 6 | Sep 26, 2024 | clinicaltrials |
| NCT02994953 | A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)(COMBO) | terminated | Phase 1 | 52 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 7 | Sep 20, 2024 | clinicaltrials |
| NCT03558711 | PSMA-PET/CT for Prostate Cancer(NGP1) | completed | Phase 1 | 6 | University Hospital, GhentOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03873883 | First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer(IO-001) | completed | Phase 1 | 119 | iTeos TherapeuticsINDUSTRY | 6 | Sep 19, 2024 | clinicaltrials |
| NCT04335253 | First-In-Human Study of EOS884448 in Participants with Advanced Cancers. | completed | Phase 1 | 40 | iTeos TherapeuticsINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05117177 | New Formulation Study of Inupadenant (EOS100850) in Patients with Cancer | completed | Phase 1 | 57 | iTeos TherapeuticsINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT02454062 | A Trial of TAS-114 in Combination With S-1 | completed | Phase 1 | 120 | Taiho Oncology, Inc.INDUSTRY | 4 | Sep 4, 2024 | clinicaltrials |
| NCT03267316 | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors(CANFOUR) | completed | Phase 1 / Phase 2 | 167 | Cantargia ABINDUSTRY | 11 | Aug 22, 2024 | clinicaltrials |
| NCT01970865 | A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations | completed | Phase 1 / Phase 2 | 364 | PfizerINDUSTRY | 14 | Aug 12, 2024 | clinicaltrials |
| NCT02353143 | Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia(ARMY) | terminated | Phase 1 | 71 | Menarini GroupINDUSTRY | 5 | Aug 12, 2024 | clinicaltrials |
| NCT02509507 | Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611(MASTERKEY-318) | completed | Phase 1 / Phase 2 | 127 | AmgenINDUSTRY | 9 | Aug 6, 2024 | clinicaltrials |
| NCT03978611 | A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment | terminated | Phase 1 | 11 | Bristol-Myers SquibbINDUSTRY | 6 | Jul 24, 2024 | clinicaltrials |
| NCT02826564 | Trial of Stereotactic Body Radiotherapy With Concurrent Pembrolizumab in Metastatic Urothelial Cancer | completed | Phase 1 | 18 | University Hospital, GhentOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT03784066 | Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity(DUTRELASCO) | unknown | Phase 1 / Phase 2 | 21 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 3, 2024 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials